An update from Reviva Pharmaceuticals Holdings ( (RVPH) ) is now available.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Reviva Pharmaceuticals announced an underwriting agreement with Citizens JMP Securities for a public offering, raising $18 million through the sale of common stock and warrants. The net proceeds are intended for research and development, working capital, and general corporate purposes. This move aims to strengthen Reviva’s financial position and support its drug development activities.
More about Reviva Pharmaceuticals Holdings
Reviva Pharmaceuticals Holdings, Inc. is a late-stage biopharmaceutical company focused on developing therapies for central nervous system, inflammatory, and cardiometabolic diseases. The company’s pipeline includes drug candidates such as brilaroxazine and RP1208, with granted composition of matter patents in the United States, Europe, and other countries.
YTD Price Performance: -55.34%
Average Trading Volume: 1,347,700
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $46.82M
For detailed information about RVPH stock, go to TipRanks’ Stock Analysis page.
